<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00031928</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069240</org_study_id>
    <secondary_id>NCI-90-C-0095K</secondary_id>
    <secondary_id>BCM-H-3241</secondary_id>
    <nct_id>NCT00031928</nct_id>
  </id_info>
  <brief_title>Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors</brief_title>
  <official_title>Phase I Study of Intrathecal Mafosfamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase I trial to determine the effectiveness of mafosfamide in treating patients who&#xD;
      have progressive or refractory meningeal tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the qualitative and quantitative toxicity of mafosfamide in patients with&#xD;
           progressive or refractory meningeal malignancy.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of this drug in these patients.&#xD;
&#xD;
        -  Determine the cerebrospinal fluid pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive intrathecal mafosfamide over 20 minutes twice weekly for 6 weeks (induction&#xD;
      therapy). Patients then receive intrathecal mafosfamide once weekly for 4 weeks&#xD;
      (consolidation therapy), twice a month for 4 months, and then monthly thereafter (maintenance&#xD;
      therapy) in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of mafosfamide until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3000 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mafosfamide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of leukemia or lymphoma with meningeal involvement defined as cerebrospinal&#xD;
             fluid cell count at least 5/mm^3 AND evidence of blast cells on cytospin preparation&#xD;
             or by cytology OR&#xD;
&#xD;
          -  Diagnosis of other solid tumor with meningeal involvement defined as presence of tumor&#xD;
             cells on cytospin preparation or cytology OR presence of measurable meningeal disease&#xD;
             on CT or MRI scan&#xD;
&#xD;
          -  Meningeal malignancy must be progressive or refractory to conventional therapy&#xD;
&#xD;
               -  Meningeal malignancies secondary to an underlying solid tumor are allowed at&#xD;
                  initial diagnosis provided there is no conventional therapy&#xD;
&#xD;
          -  No concurrent bone marrow relapse in leukemia or lymphoma patients&#xD;
&#xD;
          -  No clinical evidence of obstructive hydrocephalus or compartmentalization of the&#xD;
             cerebrospinal fluid flow as documented by a radioisotope indium In 111 or technetium&#xD;
             Te 99-DTPA flow study&#xD;
&#xD;
               -  Patients demonstrating restored flow after focal radiotherapy are allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 3&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 8 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  No clinically significant liver function abnormalities&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  No clinically significant renal function abnormalities&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after study&#xD;
&#xD;
          -  No clinically significant metabolic parameter abnormalities (e.g., electrolytes,&#xD;
             calcium, and phosphorus)&#xD;
&#xD;
          -  No significant systemic illness (e.g., infection)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Recovered from prior immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 1 week since prior intrathecal chemotherapy (2 weeks for cytarabine&#xD;
             (liposomal)) and recovered&#xD;
&#xD;
          -  Concurrent systemic chemotherapy to control systemic or bulk CNS disease allowed with&#xD;
             the following exceptions:&#xD;
&#xD;
               -  No phase I agent&#xD;
&#xD;
               -  No agent that significantly penetrates the CNS (e.g., high-dose systemic&#xD;
                  methotrexate (more than 1 g/m^2), high-dose cytarabine (more than 2 g/m^2), IV&#xD;
                  mercaptopurine, fluorouracil, topotecan, or thiotepa)&#xD;
&#xD;
               -  No agent known to have serious unpredictable CNS side effects&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  At least 8 weeks since prior craniospinal irradiation&#xD;
&#xD;
          -  Local radiotherapy for symptomatic or bulky CNS disease must be given prior to&#xD;
             induction therapy&#xD;
&#xD;
          -  No concurrent whole brain or craniospinal irradiation&#xD;
&#xD;
               -  Concurrent partial brain (e.g., base of brain) or limited-field spinal&#xD;
                  radiotherapy for asymptomatic bulky (radiographically visible) CNS disease&#xD;
                  allowed&#xD;
&#xD;
          -  Total CNS radiotherapy dose must not exceed accepted safe tissue tolerances&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 1 week since any prior CNS therapy&#xD;
&#xD;
          -  At least 7 days since prior intrathecal investigational agent&#xD;
&#xD;
          -  At least 14 days since prior systemic investigational agent&#xD;
&#xD;
          -  No other concurrent intrathecal or systemic investigational agent&#xD;
&#xD;
          -  No other concurrent intrathecal or systemic therapy to treat meningeal malignancy&#xD;
&#xD;
          -  No other concurrent intrathecal therapy or agent that significantly penetrates the&#xD;
             blood-brain barrier&#xD;
&#xD;
          -  No concurrent agent known to have serious unpredictable CNS side effects&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan M. Blaney, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Texas Children's Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-0700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center at Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Research Center, Inc.</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2003</verification_date>
  <study_first_submitted>March 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <keyword>leptomeningeal metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mafosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

